Kwality (KPL) | Financial Analysis & Statements
Kwality Pharmaceuticals Ltd. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Sep 2025Income Metrics
Revenue
1.1B
Gross Profit
564.3M
50.81%
Operating Income
204.0M
18.37%
Net Income
141.2M
12.71%
EPS (Diluted)
₹13.60
Balance Sheet Metrics
Total Assets
4.5B
Total Liabilities
1.8B
Shareholders Equity
2.6B
Debt to Equity
0.70
Cash Flow Metrics
Operating Cash Flow
-36.2M
Free Cash Flow
-14.1M
Revenue & Profitability Trend
Quarter Income Flow
Sep 30, 2025
Annual Income Flow
2025
Kwality Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 3.7B | 3.1B | 2.5B | 4.6B | 2.6B |
| Cost of Goods Sold | 1.9B | 1.6B | 1.2B | 2.1B | 1.7B |
| Gross Profit | 1.8B | 1.4B | 1.3B | 2.5B | 906.8M |
| Gross Margin % | 49.4% | 46.8% | 52.4% | 53.9% | 34.6% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 227.2M | 125.7M | 190.8M | 312.0M | 281.0M |
| Other Operating Expenses | 359.0M | 321.8M | 218.0M | 229.5M | 174.7M |
| Total Operating Expenses | 586.2M | 447.5M | 408.8M | 541.5M | 455.7M |
| Operating Income | 621.0M | 467.9M | 457.7M | 1.6B | 226.6M |
| Operating Margin % | 16.8% | 15.2% | 18.2% | 35.3% | 8.6% |
| Non-Operating Items | |||||
| Interest Income | 1.6M | 1.3M | 1.2M | 1.2M | 1.8M |
| Interest Expense | 98.8M | 103.9M | 60.2M | 29.2M | 26.8M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 541.4M | 311.0M | 255.7M | 1.6B | 212.7M |
| Income Tax | 143.4M | 74.8M | 62.9M | 416.3M | 63.8M |
| Effective Tax Rate % | 26.5% | 24.1% | 24.6% | 25.8% | 30.0% |
| Net Income | 398.0M | 236.2M | 192.8M | 1.2B | 148.9M |
| Net Margin % | 10.8% | 7.7% | 7.7% | 26.3% | 5.7% |
| Key Metrics | |||||
| EBITDA | 822.8M | 681.4M | 630.3M | 1.8B | 304.6M |
| EPS (Basic) | ₹38.40 | ₹22.93 | ₹18.67 | ₹115.64 | ₹14.60 |
| EPS (Diluted) | ₹38.40 | ₹22.93 | ₹18.67 | ₹115.64 | ₹14.60 |
| Basic Shares Outstanding | 10376198 | 10376198 | 10376198 | 10376198 | 10373904 |
| Diluted Shares Outstanding | 10376198 | 10376198 | 10376198 | 10376198 | 10373904 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Kwality Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 120.2M | 22.6M | 30.7M | 91.3M | 58.1M |
| Short-term Investments | 27.4M | 36.9M | 42.9M | 38.2M | 44.4M |
| Accounts Receivable | 1.5B | 1.1B | 716.9M | 691.3M | 357.1M |
| Inventory | 834.7M | 783.9M | 863.1M | 533.6M | 173.6M |
| Other Current Assets | 184.6M | 1.0K | -1.0K | -1.0K | 4.0K |
| Total Current Assets | 2.8B | 2.4B | 2.1B | 2.3B | 1.1B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 458.3M | 417.0M | 339.3M | 239.8M | 111.6M |
| Goodwill | 17.1M | - | - | - | - |
| Intangible Assets | 17.1M | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | -1.0K | 124.4M | 116.4M | 88.9M | 26.0K |
| Total Non-Current Assets | 1.6B | 1.5B | 1.5B | 1.1B | 603.6M |
| Total Assets | 4.5B | 3.9B | 3.5B | 3.4B | 1.7B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 557.9M | 443.2M | 351.9M | 345.1M | 262.1M |
| Short-term Debt | 973.3M | 785.6M | 629.6M | 337.2M | 229.6M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 3.1M | 6.6M | 1.0K | -1.0K | 2.0K |
| Total Current Liabilities | 1.7B | 1.5B | 1.3B | 1.4B | 782.9M |
| Non-Current Liabilities | |||||
| Long-term Debt | 151.2M | 195.6M | 273.0M | 202.9M | 182.6M |
| Deferred Tax Liabilities | 0 | 0 | 4.1M | 2.7M | 0 |
| Other Non-Current Liabilities | 1.0K | - | - | 1.0K | 91.8M |
| Total Non-Current Liabilities | 153.7M | 197.8M | 286.2M | 213.2M | 281.2M |
| Total Liabilities | 1.8B | 1.7B | 1.5B | 1.6B | 1.1B |
| Equity | |||||
| Common Stock | 103.8M | 103.8M | 103.8M | 103.8M | 103.8M |
| Retained Earnings | 2.4B | 2.0B | 1.8B | 1.6B | 414.3M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 2.6B | 2.2B | 2.0B | 1.8B | 598.5M |
| Key Metrics | |||||
| Total Debt | 1.1B | 981.2M | 902.6M | 540.1M | 412.3M |
| Working Capital | 1.1B | 908.4M | 812.5M | 883.3M | 276.1M |
Balance Sheet Composition
Kwality Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 541.4M | 311.0M | 255.7M | 1.6B | 212.7M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | - | - | - |
| Working Capital Changes | -251.5M | -318.7M | 3.4M | -1.1B | -33.3M |
| Operating Cash Flow | 387.3M | 162.9M | 319.6M | 559.8M | 204.7M |
| Investing Activities | |||||
| Capital Expenditures | -232.2M | -257.3M | -458.1M | -551.5M | -232.6M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | - | - | - | -483.0K | -1.3M |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -269.6M | -265.3M | -485.6M | -631.0M | -233.8M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 87.9M | 40.6M | 115.5M | 143.7M | 151.7M |
| Debt Repayment | -133.6M | -112.6M | -45.3M | -123.4M | -3.7B |
| Financing Cash Flow | -45.6M | -72.0M | 70.1M | 56.6M | -3.6B |
| Free Cash Flow | 277.2M | 131.4M | -62.9M | 54.4M | 33.1M |
| Net Change in Cash | 72.1M | -174.4M | -95.9M | -14.6M | -3.6B |
Cash Flow Trend
Kwality Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
30.86
Price to Book
6.02
Price to Sales
3.78
PEG Ratio
0.35
Profitability Ratios
Profit Margin
12.25%
Operating Margin
20.79%
Return on Equity
15.19%
Return on Assets
8.91%
Financial Health
Current Ratio
1.88
Debt to Equity
38.29
Beta
0.13
Per Share Data
EPS (TTM)
₹54.54
Book Value per Share
₹279.50
Revenue per Share
₹444.37
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| KPL | 17.5B | 30.86 | 6.02 | 15.19% | 12.25% | 38.29 |
| Sun Pharmaceutical | 3.9T | 36.73 | 5.15 | 15.08% | 19.21% | 6.68 |
| Divi's Laboratories | 1.7T | 67.11 | 10.82 | 14.64% | 24.04% | 0.58 |
| Sun Pharma Advanced | 46.7B | -13.65 | -13.55 | 157.88% | -53.22% | -1.21 |
| Innova Captab | 41.4B | 31.20 | 4.05 | 13.37% | 8.85% | 32.95 |
| Gujarat Themis | 35.4B | 73.73 | 13.36 | 19.64% | 29.99% | 27.04 |
Financial data is updated regularly. All figures are in the company's reporting currency.





